Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Hobbs FR. et al, (2024), Journal of Infection, 89
Hobbs FR. et al, (2024), Journal of Infection, 89